Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tandospirone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tandospirone SCHEMBL16339864 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL22693814 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL4445506 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL22381099 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL49026 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL13532602 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL11011731 | 0.95 | DRD2 (0.91) | DRD2HTR1ADRD4 | |
| SCHEMBL10925913 | 0.94 | DRD2 (0.90) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL15383602 | 0.91 | DRD2 (0.85) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL15383590 | 0.91 | DRD2 (0.84) | DRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119896653-A | Percutaneous absorption preparation | 湖南慧泽生物医药科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20160375016-A1 | METHODS FOR REDUCING ANXIETY AND IMPULSIVITY IN SUBJECTS INITIATING TREATMENT WITH SEROTONIN REUPTAKE INHIBITORS | UNIV JOHNS HOPKINS (US) | 2016-12-29 | — | — | US | claimed |
| EP-2367528-A1 | COMPOSITIONS OF TOPICAL OCULAR SOLUTIONS TO DELIVER EFFECTIVE CONCENTRATIONS OF ACTIVE AGENT TO THE POSTERIOR SEGMENT OF THE EYE | Alcon Research, Ltd. (US) | 2011-09-28 | — | — | EP | claimed |
| WO-2010074961-A1 | COMPOSITIONS OF TOPICAL OCULAR SOLUTIONS TO DELIVER EFFECTIVE CONCENTRATIONS OF ACTIVE AGENT TO THE POSTERIOR SEGMENT OF THE EYE | ALCON RESEARCH, LTD. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100160342-A1 | Compositions of Topical Ocular Solutions to Deliver Effective Concentrations of Active Agent to the Posterior Segment of the Eye | ALCON RESEARCH, LTD. (US) | 2010-06-24 | — | — | US | claimed |
| CN-119896653-A | Percutaneous absorption preparation | 湖南慧泽生物医药科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-108686214-B | Compound antihypertensive medicinal composition and application thereof | 四川科瑞德制药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-108619100-B | Azaspirone medicine injection and preparation method and application thereof | 四川科瑞德制药股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-106749196-B | 5-hydroxytryptamine receptor agonist | 四川科瑞德制药股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-106800550-B | 5-hydroxytryptamine receptor agonist | 四川科瑞德制药股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-108686214-A | Compound antihypertensive drug composition and application thereof | 四川科瑞德制药股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-9707173-B2 | Pharmaceutical suspension | ALCON RESEARCH, LTD. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2010027907-A2 | PHARMACEUTICAL COMPOSITION HAVING RELATIVELY LOW IONIC STRENGTH | ALCON RESEARCH, LTD. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056537-A1 | PHARMACEUTICAL COMPOSITION HAVING RELATIVELY LOW IONIC STRENGTH | ALCON RESEARCH, LTD. | 2010-03-04 | — | — | US | disclosed |
| US-6566361-B2 | Concurrent administration of acetaminophen with an azapirone such as buspirone. | LABORATORIES, UPSA (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20020032215-A1 | Azapirone pain treatment | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
| US-5330762-A | Tandospiaine antidepressive therapy | ALZA CORPORATION (US) | 1994-07-19 | — | — | US | disclosed |
| US-5246711-A | Dosage form for treating dysthymia | ALZA CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
| US-5246710-A | Dosage form for treating cyclothymia | ALZA CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
| US-5185158-A | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same | ALZA CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032215-A1 | Azapirone pain treatment | OPRK1, OPRL1, NR3C1 | DRD2 863/4885HTR1A 189/4885DRD4 1194/4885 |
| US-20100056537-A1 | PHARMACEUTICAL COMPOSITION HAVING RELATIVELY LOW IONIC STRENGTH | KCNN3, KCNJ11, KCNJ1 | DRD2 555/4885HTR1A 4660/4885DRD4 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.